Innoviva, Inc. (INVA)
NASDAQ: INVA · Real-Time Price · USD
23.69
+0.33 (1.41%)
At close: Apr 28, 2026, 4:00 PM EDT
23.70
+0.01 (0.04%)
After-hours: Apr 28, 2026, 7:42 PM EDT
Innoviva Employees
Innoviva had 159 employees as of December 31, 2025. The number of employees increased by 32 or 25.20% compared to the previous year.
Employees
159
Change (1Y)
32
Growth (1Y)
25.20%
Revenue / Employee
$2,586,969
Profits / Employee
$1,705,440
Market Cap
1.75B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 600 |
| Vir Biotechnology | 367 |
| Nurix Therapeutics | 317 |
| Syndax Pharmaceuticals | 298 |
| Harmony Biosciences Holdings | 293 |
| Nanobiotix | 103 |
| Taysha Gene Therapies | 99 |
| Rapport Therapeutics | 84 |
INVA News
- 7 weeks ago - Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report - Business Wire
- 2 months ago - Innoviva Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference - Transcripts
- 2 months ago - Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress - Business Wire
- 2 months ago - Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Business Wire
- 4 months ago - U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents - Business Wire
- 4 months ago - US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections - Reuters
- 4 months ago - Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea - Business Wire
- 5 months ago - Innoviva Transcript: Piper Sandler 37th Annual Healthcare Conference - Transcripts